SCHEMBL6017384

SCHEMBL6017384

CCCCCCCCCCCCCCCCN(CC(O)COc1ccc(CC(N)=O)cc1)C(C)C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.55
LMNA P02545 3/20 0.55
KDM4E B2RXH2 2/20 0.55
ADRB2 P07550 1/20 0.55
ADRB1 P08588 1/20 0.55
CNR1 P21554 1/20 0.55
ADRA1D P25100 1/20 0.55
ADRA1A P35348 1/20 0.55
ADRA1B P35368 1/20 0.55
CYP1A2 P05177 1/20 0.55
GLA P06280 1/20 0.55
CYP3A4 P08684 1/20 0.55
TSHR P16473 1/20 0.55
NFKB1 P19838 1/20 0.55
THPO P40225 1/20 0.55
BLM P54132 1/20 0.55
PMP22 Q01453 1/20 0.55
PLA2G4B P0C869 1/20 0.46
ABCB1 P08183 2/20 0.45
S1PR1 P21453 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22398925 0.91 LMNA (0.59) TDP1LMNAKDM4EADRB2ADRB1
SCHEMBL662466 0.88 LMNA (0.64) TDP1LMNAKDM4EADRB2ADRB1
SCHEMBL23269346 0.88 LMNA (0.64) TDP1LMNAKDM4EADRB2ADRB1
SCHEMBL25722230 0.84 LMNA (0.59) TDP1LMNAKDM4EADRB2ADRB1
SCHEMBL19122257 0.83 LMNA (0.54) TDP1LMNAKDM4EADRB2ADRB1
SCHEMBL11925285 0.81 LMNA (0.64) TDP1LMNAKDM4EADRB2ADRB1
SCHEMBL11929214 0.80 LMNA (0.63) TDP1LMNAKDM4EADRB2ADRB1
SCHEMBL661905 0.78 LMNA (0.60) TDP1LMNAKDM4EADRB2ADRB1
SCHEMBL14283101 0.76 LMNA (0.67) TDP1LMNAKDM4EADRB2ADRB1
SCHEMBL4682860 0.75 PLA2G4B (0.65) LMNAKDM4ECYP1A2TSHRPLA2G4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0973552-B1 IMPROVEMENTS IN OR RELATING TO DIAGNOSTIC/THERAPEUTIC AGENTS AMERSHAM HEALTH AS (NO) 2006-03-01 EP disclosed
US-20040141922-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2004-07-22 US disclosed
US-20020102215-A1 Diagnostic/therapeutic agents NYCOMED IMAGING AS 2002-08-01 US disclosed
US-6264917-B1 MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT NYCOMED IMAGING AS (NO) 2001-07-24 US disclosed
US-6261537-B1 TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES NYCOMED IMAGING AS (NO) 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040141922-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 TDP1 1645/4885LMNA 1461/4885KDM4E 4466/4885
US-20020102215-A1 Diagnostic/therapeutic agents BID, FUS, FABP1 TDP1 1721/4885LMNA 1552/4885KDM4E 4426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.